# PT-141: Research Overview — Gurl Peptide > A literature summary of PT-141 (bremelanotide), the lead desire-and-arousal research peptide: central MC4R mechanism, Phase 3 HSDD trial results, FDA approval scope and safety signals. Bremelanotide — a cyclic melanocortin heptapeptide that acts in the hypothalamus on desire, not on blood vessels. FDA-approved for one specific group; off-label for everyone else. ## The short version PT-141 is the research-chemical name for **bremelanotide**, a synthetic cyclic heptapeptide that activates melanocortin receptors — chiefly MC4R — in the hypothalamus and limbic system. Unlike drugs that act on blood vessels, PT-141 works centrally on the brain circuits that govern sexual motivation and desire [7]. It has an FDA-approved pharmaceutical form: bremelanotide injection was approved in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — a single, narrow indication [5]. Here is the honest part. The approval covers one group and one condition. Men, postmenopausal women, and any use for general performance or enhancement are off-label. Phase 3 trial results showed statistically significant but modest improvements in desire and distress [3]. Nausea affected about 40% of women over long-term use [4]. The most common side effects are nausea, flushing and headache. Research-grade PT-141 exists outside the pharmaceutical approval framework with no quality oversight. This page summarizes what was studied; it is not advice and lists no human dose. ## What it is PT-141 is a cyclic heptapeptide lactam with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The lactam bridge between the Asp and Lys side chains gives it a rigid ring structure and enzymatic resistance. It is a structural relative of Melanotan II — specifically a derivative with the C-terminal amide replaced by a carboxylic acid, which reduces unwanted receptor-subtype activity. The pharmaceutical form, bremelanotide, is administered as a 1.75 mg subcutaneous injection on an as-needed basis. Research-grade material circulates outside any pharmaceutical quality system. PT-141 is not a PDE-5 inhibitor and does not act on vascular smooth muscle. ## How it works PT-141 activates the melanocortin 4 receptor (MC4R) and, to a lesser degree, MC3R. These receptors are concentrated in the hypothalamus — particularly the medial preoptic area — and in limbic structures involved in motivation and reward. By stimulating MC4R, the peptide is thought to engage dopaminergic pathways that govern sexual desire and arousal [7]. A 2022 randomized, double-blind, crossover fMRI study in 31 premenopausal women with HSDD tested this mechanism directly: MC4R agonism significantly increased sexual desire for up to 24 hours and altered brain processing of erotic stimuli, enhancing amygdala-insula functional connectivity and cerebellar activity [2]. This provides mechanistic neuroimaging support for the central model. A parallel rodent study found that PT-141 selectively stimulated appetitive solicitational sexual behaviors in female rats — specifically desire-oriented approach behaviors — without affecting other motor activity, consistent with a central rather than peripheral site of action [6]. In female Syrian hamsters, bremelanotide did not alter MC3R/MC4R mRNA expression in the mesolimbic dopamine system and did not enhance sexual reward (conditioned place preference) in that specific model, suggesting the VTA-nucleus-accumbens reward circuit may not be its primary locus [1]. The mechanistic picture is one of central hypothalamic desire circuits, not a simple reward pathway. ## What the research shows *Phase 3 (RECONNECT trials, n=1267).* Two identical randomized, double-blind, placebo-controlled crossover trials of bremelanotide 1.75 mg subcutaneous as-needed over 24 weeks found statistically significant improvements in both coprimary endpoints: integrated FSFI-desire score (+0.35 vs placebo, P<.001) and reduced desire-related distress on the FSDS-DAO item 13 (-0.33 vs placebo, P<.001). Most common adverse events were nausea, flushing and headache [3]. *Long-term extension (52 weeks, n=684).* No new safety signals emerged. Sexual-desire improvements were sustained. The most common drug-related treatment-emergent adverse events were nausea (40.4%), flushing (20.6%) and headache (12.0%) [4]. *Early central mechanism (men, nonhuman primates, rats).* In 2003 research, PT-141 produced dose-dependent penile erections in rats and nonhuman primates, activated hypothalamic neurons (increased c-Fos staining), and produced rapid erectile activity in men with erectile dysfunction — consistent with a central mechanism [7]. *Pharmacokinetics and prescribing (FDA label).* The US prescribing information specifies the approved HSDD indication, terminal half-life approximately 2.7 hours (range 1.9-4.0 h), volume of distribution 25.0 L, clearance 6.5 L/hr, and a warning on transient blood-pressure increase. Contraindicated in uncontrolled hypertension or cardiovascular disease. Maximum one dose per 24 hours, no more than eight doses per month [5]. ## Reported effects, cautions & safety The documented cautions for PT-141 are specific and well-characterized from the clinical trial record. **Cited safety signals from the literature:** - *Nausea is common.* Affecting roughly 40% of participants over long-term use, nausea is the principal tolerability issue and a notable driver of discontinuation [4]. - *Transient blood-pressure increase.* The FDA label carries a warning on this. PT-141 is contraindicated in uncontrolled hypertension or known cardiovascular disease [5]. - *Hyperpigmentation* of the face, gums, and breasts is reported with repeated frequent dosing, attributed to MC1R activation. - *Modest effect size.* Critical re-analyses argue the trial effects, while statistically significant, are small and raise questions about clinical meaningfulness [3]. - *Approved only for premenopausal women with HSDD.* Use in men, postmenopausal women, or for performance enhancement is off-label and lacks Phase 3 support [5]. - *Research-grade material is unregulated.* Identity, purity and concentration are unverified outside pharmaceutical-grade studies. **Field reports (anecdotal, not clinical evidence):** People in research-use communities describe a heightened sense of sexual interest or desire, sometimes within hours of administration. Others report little to no perceptible subjective change — a reminder that hormonal or neurological effects measured in a trial do not always translate to a felt experience. These are anecdotal observations, reported separately from the cited clinical data, and carry no dosing implication. ## Where it fits in desire and arousal research PT-141 is the most clinically advanced peptide on this desk. Its central-melanocortin mechanism is well characterized, its Phase 3 human data are the strongest of the three, and it has a real pharmaceutical approval — though that approval covers only one specific group and condition [5]. Read alongside [Kisspeptin](/kisspeptin), which acts upstream on the entire reproductive hormone axis, and [Melanotan II](/melanotan-2), its broader-acting structural precursor, PT-141 illustrates what focused receptor-selectivity can achieve — and where the limits of even an approved compound still lie. See the [comparison page](/compare) for how it lines up against the others. ![PT-141 research illustration](/images/pt-141.webp) --- Peer-reviewed citations on desire and arousal research — a digest, not a prescription, not a vendor.